What Is Hyperhidrosis? Types and Diagnosis

Hyperhidrosis is excessive sweating, but the subtype changes the next step#

Hyperhidrosis is sweating beyond what the body needs to regulate temperature. The clinically useful distinction is between primary focal hyperhidrosis, which follows a characteristic pattern at specific body sites, and secondary hyperhidrosis, in which another condition, medication, or physiologic state may be driving the sweating.[1]

The word does not identify a cause by itself. It also does not mean every visible sweat mark is a disorder. Frequency, distribution, timing, and interference with daily life all matter.

Primary focal hyperhidrosis has a recognizable pattern#

A 2004 multispecialty working group defined primary focal hyperhidrosis as excessive, bilateral, roughly symmetric sweating at one or more focal sites, commonly the underarms, palms, soles, or face.[1] Features that support the pattern include:

• sweating on both sides in a similar distribution;
• onset before age 25;
• at least weekly episodes;
• interference with daily activities;
• a family history; and
• no focal sweating during sleep.[1]

These are clinical clues, not a home scoring system that proves the diagnosis. A history and examination still need to rule out a more likely secondary explanation.

Family history is only one supporting clue. The genetics evidence review explains why current studies do not establish inevitable inheritance or a diagnostic consumer DNA test.

Secondary hyperhidrosis is a cause category, not one disease#

Secondary sweating may be related to medication effects, endocrine or neurologic conditions, infection, menopause, malignancy, or other causes. It is more likely to enter the differential when sweating begins suddenly, affects much of the body, is asymmetric, or occurs during sleep.[1]

For a focused review of one commonly suspected trigger, see what controlled caffeine studies found.

Night sweats are particularly nonspecific. A systematic review found that prevalence varied widely across populations and that many reported cases did not lead to a clear cause.[2] That means night sweating is not automatically evidence of a serious disease, but it also does not fit the classic “absent during sleep” feature of primary focal hyperhidrosis. Persistent or concerning night sweats deserve a primary-care evaluation rather than an online diagnosis.

Severity is measured by life interference as well as sweat#

The Hyperhidrosis Disease Severity Scale, or HDSS, is a four-point patient-reported measure. It ranges from sweating that is never noticeable and never interferes with daily activities to sweating that is intolerable and always interferes.[3] Clinical trials often use improvement on that scale to describe response.

The HDSS is useful because sweat burden is not captured by one photograph or one measurement. A person may be deeply limited by wet hands at work, soaked footwear, or underarm clothing changes even when sweating is not visible during an appointment. The scale does not determine the cause or select a treatment.

Hyperhidrosis is organized by body site#

The affected site changes both practical burden and evidence:

• Axillary: underarm sweating, with topical antiperspirants, prescription cloths, Botox, and microwave treatment among the studied options.
• Palmar: hand sweating, where aluminum chloride and iontophoresis have controlled evidence.
• Plantar: foot sweating, where topical antiperspirants and iontophoresis may be considered.
• Craniofacial: face or scalp sweating, which needs its own safety and treatment discussion.

Several sites can be affected at once. A treatment with an underarm indication should not be assumed to have the same regulatory status or evidence at the hands, feet, or face.

Diagnosis comes before a treatment ranking#

For a classic primary focal pattern, the history and examination may be more important than broad laboratory testing.[1] When the pattern is atypical, a clinician can target testing to the suspected cause rather than ordering every possible test.

After the subtype and body site are clear, treatment usually progresses from lower-burden local measures toward prescriptions, devices, injections, systemic medication, or procedures as needed. The hyperhidrosis treatment evidence map keeps those options attached to the sites and study designs that support them.

Frequently asked questions#

Is hyperhidrosis just sweating a lot?#

It is excessive sweating that is out of proportion to thermal needs, but clinical interpretation also uses distribution, timing, recurrence, and life interference. Amount alone does not identify the subtype.[1]

Can hyperhidrosis start in adulthood?#

It can, but later or sudden onset makes a secondary-cause review more important. Primary focal disease often starts before age 25.[1]

Does primary hyperhidrosis happen during sleep?#

The classic diagnostic pattern is absent during sleep. Night sweats are nonspecific and deserve a broader assessment when persistent or concerning.[1][2]

Is hyperhidrosis curable?#

Some treatments reduce sweating for a period or damage local sweat glands, but “cure” is too broad across subtypes, body sites, and modalities. Evidence is better expressed as response, duration, maintenance, and adverse effects.

Bottom line#

Hyperhidrosis is not one uniform condition. Primary focal hyperhidrosis is usually bilateral, site-specific, recurrent, early-onset, disruptive, and absent during sleep. Sudden, generalized, asymmetric, or nocturnal sweating points toward a secondary-cause evaluation.[1] That distinction should be settled before choosing a treatment approach.

This article is educational and cannot diagnose primary or secondary hyperhidrosis.

References#

1. Hornberger J, Grimes K, Naumann M, et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004;51(2):274-286. PubMed PMID 15280848

2. Mold JW, Holtzclaw BJ, McCarthy L. Night sweats: a systematic review of the literature. J Am Board Fam Med. 2012. PubMed PMID 23136329

3. Solish N, Benohanian A, Kowalski JW, Canadian Dermatology Study Group. Prospective open-label study of botulinum toxin type A in axillary hyperhidrosis: effects on functional impairment and quality of life. Dermatol Surg. 2005. PubMed PMID 15871315